Suki Raises $90M Series E for AI Scribe, Targets $60-80M Annual Revenue
Suki secured $90 million in Series E funding led by Healthier Capital to scale its AI ambient scribe platform and integrate agentic workflows for healthcare providers.
Key points
- Suki raised $90 million in a Series E funding round.
- Healthier Capital led the investment round.
- The company projects $60 million to $80 million in annual revenue.
Suki, an artificial intelligence ambient scribe company serving healthcare providers, has raised $90 million in a Series E funding round. The investment was led by Healthier Capital, according to a report by Axios.
CEO Punit Soni told Axios Pro that the capital will be used to scale operations and add agentic workflows to the platform. A source familiar with the company’s financials told Axios that Suki projects between $60 million and $80 million in revenue for the current year.
Funding and Strategic Focus
The $90 million injection marks a significant step for Suki as it moves beyond basic transcription services. The company is focusing on agentic workflows, which implies a shift toward more autonomous AI capabilities within clinical environments. Healthier Capital’s leadership of the round signals strong investor confidence in this specific trajectory for healthcare AI tools.
Market Position and Financial Outlook
Suki’s projected revenue of $60 million to $80 million this year suggests substantial commercial traction. This financial performance underpins the valuation that attracted Series E interest. The company continues to target healthcare providers who rely on ambient scribing to reduce administrative burdens and improve documentation accuracy during patient interactions.
Defender's checklist
Organizations adopting AI scribes should monitor vendor financial health and product roadmaps. Understanding the shift toward agentic workflows is critical for assessing long-term dependency. Stakeholders should verify data handling practices as AI capabilities expand.
What to do and how to stay safe: Suki
- Review vendor contracts to understand data ownership and usage rights for AI-generated content.
- Evaluate the specific agentic workflows being introduced to ensure they align with clinical safety standards.
- Monitor vendor financial disclosures to assess long-term product viability and support continuity.
- Conduct regular audits of AI output for accuracy and compliance with healthcare regulations.
Step-by-step guide: Implementing AI Usage Policies at Work: A Step-by-Step Framework
General security guidance from the InfoSec Ledger newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
How much funding did Suki raise in its latest round?
Suki raised $90 million in a Series E funding round.
Which firm led Suki's Series E investment?
Healthier Capital led the Series E investment round for Suki.
What are Suki's projected revenues for this year?
Sources say Suki projects between $60 million and $80 million in revenue this year.




